# Investment Dossier: EXEL
**Rank: #3 | Composite Score: 7.81/10**
**Generated: 2026-01-05 (as-of date)**

## Executive Summary
- Company: Exelixis, Inc.
- Price: $42.40
- Market Cap: $11.41B
- Cash: $376M
- Clinical Stage: phase_3
- Active Trials: 25/50

## Score Breakdown

| Component | Score | Weight | Contribution |
|-----------|-------|--------|--------------|
| Stage | 8.0/10 | 30% | 2.40 |
| Cash (capped) | 3.6/10 | 25% | 0.91 |
| Runway | 10.0/10 | 25% | 2.50 |
| Pipeline | 10.0/10 | 20% | 2.00 |
| **Composite** | **7.81/10** | 100% | **7.81** |

## Financial Reality Check
- Cash: $376M
- Estimated Runway: ~25mo
- Market Cap: $11.41B
- Daily Volume: 2,600,985 shares

## Freshness & Point-in-Time Discipline

**As-of Date:** 2026-01-05

**SEC Financial Data:**
- Period End: 2025-10-01
- Period End Age: 96 days
- Filed Date: 2026-01-05
- Status: FRESH (<365 days)

**Market Data:**
- Source: Yahoo Finance (real-time)
- Last Update: 2026-01-05

## Data Quality
- Overall Coverage: 85%
- Financial Coverage: 75%
- SEC Data Status: Fresh

## Risk Warnings
- [PASS] No major risk flags identified


---
*Point-in-time validated. Algorithmically generated. Verify all data before investment decisions.*
